
-
Asalanka ton leads Sri Lanka to 244 in first Bangladesh ODI
-
UK govt backs finance minister after tears in parliament
-
US private sector shed jobs for first time in recent years: ADP
-
Chelsea sign Brazil striker Joao Pedro from Brighton
-
Farrell says slow-starting Lions still have work to do
-
French court convicts ex-Ubisoft bosses for workplace harassment
-
Freeman at the double as slick Lions romp past Reds 52-12
-
India's Jaiswal on the attack against England in second Test
-
Liverpool defender Quansah signs for Bayer Leverkusen
-
Alcaraz aims to avoid giant-killing after Wimbledon seeds tumble
-
Freeman at the double as Lions sweep past Queensland Reds 52-12
-
Iran ends cooperation with UN nuclear watchdog after Israel, US strikes
-
Matildas' defender Carpenter leaves Lyon for Chelsea
-
Public or private? Funding debate splits reeling aid sector
-
Stocks diverge as tariffs deadline looms
-
EU unveils long-delayed 2040 climate target -- with wiggle room
-
Central Europe swelters as heatwave moves east
-
Hong Kong to regain IPO crown this year, say PwC and Deloitte
-
Iran suspends cooperation with UN nuclear watchdog
-
Israel's top diplomat urges seizing chance after Trump ceasefire push
-
Australia cancels Kanye West visa over 'Heil Hitler' song
-
Israel FM calls to seize opportunity as Trump pushes for Gaza ceasefire
-
Fire that closed Heathrow traced to unrepaired transformer
-
Gaza rescuers say Israeli strikes kill 14 as Trump teases ceasefire push
-
Asian markets mixed as trade deal cut-off looms
-
Dalai Lama says he will have successor after his death
-
Demining Ukraine: from drones to risking it with a rake
-
Eggs en Provence: France's unique dinosaur egg trove
-
'I lost my battle': warming sea killing Albania fishing
-
Combs Trial: Day three of jury debate after partial verdict reached
-
Giant Trump tax bill faces make-or-break vote in Congress
-
Oasis: five favourite hits
-
'Finally': Oasis fans, young and old, gear up for reunion
-
North Korea opens massive beach resort: state media
-
'No roof' to Savea ability for ex-All Black Kaino before France Tests
-
Alcaraz faces amateur hour against young Brit at Wimbledon
-
'Writing is thinking': do students who use ChatGPT learn less?
-
Australian airline Qantas says hit by 'significant' cyberattack
-
India exporters cautiously optimistic as US tariff deadline looms
-
Real Madrid oust Juventus as Dortmund reach Club World Cup quarters
-
Relief coming for Europe after brutal heatwave
-
Fate of major trade deal with EU hangs over Mercosur summit
-
Thai veteran politician set for single day as acting PM
-
Guirassy double as Dortmund down Monterrey to reach Club World Cup quarters
-
BTS agency confirms superstars' 2026 album, tour
-
US halting some shipments of military aid to Ukraine
-
ALMA lets astronomers see building blocks of early galaxies
-
Philippines biodiversity hotspot pushes back on mining
-
Deal or no deal: What happens with Trump's July tariff deadline?
-
Canada turns to drones for reforestation after wildfires

Japanese researchers test pioneering drug to regrow teeth
People with missing teeth may be able to grow new ones, say Japanese dentists testing a pioneering drug they hope will offer an alternative to dentures and implants.
Unlike reptiles and fish, which usually replace their fangs on a regular basis, it is widely accepted that humans and most other mammals only grow two sets of teeth.
But hidden underneath our gums are the dormant buds of a third generation, according to Katsu Takahashi, head of oral surgery at the Medical Research Institute Kitano Hospital in Osaka.
His team launched clinical trials at Kyoto University Hospital in October, administering an experimental medicine to adult test subjects that they say has the potential to jumpstart the growth of these concealed teeth.
It's a technology "completely new" to the world, Takahashi told AFP.
Prosthetic treatments used for teeth lost to decay, disease or injury are often seen as costly and invasive.
So "restoring natural teeth definitely has its advantages", said Takahashi, the project's lead researcher.
Tests on mice and ferrets suggest that blocking a protein called USAG-1 can awaken the third set, and the researchers have published lab photographs of regrown animal teeth.
In a study published last year, the team said their "antibody treatment in mice is effective for tooth regeneration and can be a breakthrough in treating tooth anomalies in humans".
- 'Only the beginning' -
For now, the dentists are prioritising the "dire" needs of patients with six or more permanent teeth missing from birth.
The hereditary condition is said to affect around 0.1 percent of people, who can have severe trouble chewing, and in Japan often spend most of their adolescence wearing a face mask to hide the wide gaps in their mouth, Takahashi said.
"This drug could be a game-changer for them," he added.
The drug is therefore aimed primarily at children, and the researchers want to make it available as early as 2030.
Angray Kang, a dentistry professor at Queen Mary University of London, only knows of one other team pursuing a similar objective of using antibodies to regrow or repair teeth.
"I would say that the Takahashi group is leading the way," the immunotechnology expert, who is not connected to the Japanese research, told AFP.
Takahashi's work is "exciting and worth pursuing", Kang said, in part because an antibody drug that targets a protein nearly identical to USAG-1 is already being used to treat osteoporosis.
"The race to regenerate human teeth is not a short sprint, but by analogy a set of back-to-back consecutive ultra-marathons," he said.
"This is only the beginning."
Chengfei Zhang, a clinical professor in endodontics at the University of Hong Kong, said Takahashi's method is "innovative and holds potential".
"The assertion that humans possess latent tooth buds capable of producing a third set of teeth is both revolutionary and controversial," he told AFP.
He also cautioned that "outcomes observed in animals do not always directly translate to humans".
The results of the animal experiments raise "questions about whether regenerated teeth could functionally and aesthetically replace missing teeth", Zhang added.
- 'Over the moon' -
A confident Takahashi argues that the location of a new tooth in a mouth can be controlled, if not pinpointed, by the drug injection site.
And if it grows in the wrong place, it can be moved through orthodontics or transplantation, he said.
No young patients with the congenital disorder are taking part in the first clinical trial, as the main objective is to test the drug's safety, rather than its effectiveness.
So for now, the participants are healthy adults who have lost at least one existing tooth.
And while tooth regeneration is not the express goal of the trial this time around, there is a slim chance that it could happen to subjects anyway, Takahashi said.
If so, the researchers will have confirmed that the drug can be effective for those with acquired toothlessness -- which would be a medical triumph.
"I would be over the moon if that happens," Takahashi said.
This could be particularly welcome news in Japan, which has the second-oldest population in the world.
Health ministry data shows more than 90 percent of people aged 75 or older in Japan have at least one tooth missing.
"Expectations are high that our technology can directly extend their healthy life expectancy," Takahashi said.
F.Pedersen--AMWN